Monitor for actual sales via Form 4 filings; while the proposed sale is material in size, it reflects planned or routine disposition by a long-term holder rather than a sudden negative signal. Given Kirk’s history with the company (former Intrexon), this may be part of estate or portfolio planning.
PGEN drugs
PGEN drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 31 $3.87entry
- T+1 · 8mo ago +1.55%α +0.80% · $3.93
- T+5 · 7mo ago +6.46%α +2.52% · $4.12
- T+20 · 7mo ago +6.20%α −3.22% · $4.11
- T+60 · 5mo ago +51.42%α +39.04% · $5.86
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Randal J. Kirk, a director and 10% shareholder of Precigen, has filed a Form 144 to propose the sale of 4,814,072 shares, primarily through affiliated trusts and LLCs. The filing signals intent to sell but does not confirm execution, and it involves long-held shares acquired via private placements, service agreements, and vesting events.
Key Facts
- Reporting owner: Randal J. Kirk, Director and 10% shareholder of Precigen, Inc.
- Total shares proposed for sale: 4,814,072
- Shares to be sold by multiple affiliated entities including trusts and LLCs (e.g., R.J. Kirk Declaration of Trust, Sunset 2020 LLC, JPK and MGK family LLCs)
- Shares were acquired over time through private placements (2013–2018), RSU vesting, and service agreements
- Filing date: March 30, 2026; agent: J.P. Morgan Securities LLC
Financial Impact
Approximately $48.1 million based on PGEN's current market price of ~$10 per share (4.8M shares × $10)
Risk Factors
- Potential downward pressure on stock if sales are executed rapidly
- Perception of insider lack of confidence, especially if no prior pattern of sales exists
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001968582-26-000339 |
| Document: 0001968582-26-000339-index.html | 0001968582-26-000339 |
| Document: 0001968582-26-000339.txt | 0001968582-26-000339 |
Track record
13 reports on PGEN
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +52.17% at T+60 after the May 13, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 4, 202612d ago 8-K Bullish 6/10 Entry $4.22 to $4.66 Now $4.30 +1.90% ▲ +10.43% +7.14% vs SPY
- Aug 28, 202611w ago Insider Cluster Neutral 3/10 Entry $6.93 to $6.99 Now $4.30 −37.95% ▲ +0.79% +0.94% vs SPY
- Aug 26, 202611w ago 144 Neutral 3/10 Entry $7.19 to $7.14 Now $4.30 −40.19% ▼ −0.70% −0.96% vs SPY
- Aug 25, 202611w ago Insider Cluster Bearish 4/10 Entry $7.42 to $7.01 Now $4.30 +42.05% ▲ +5.53% +5.41% vs SPY
- Aug 25, 202611w ago Insider Cluster Neutral 2/10 Entry $7.42 to $7.01 Now $4.30 −42.05% ▼ −5.53% −5.41% vs SPY
- Aug 7, 202614w ago Insider Cluster Neutral 2/10 Entry $7.00 to $6.55 Now $4.30 −38.57% ▼ −6.43% −6.38% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $6.53 to $6.86 Now $4.30 −34.15% ▲ +5.05% +5.15% vs SPY
- Jul 1, 202619w ago Insider Cluster Bearish 5/10 Entry $5.64 to $5.53 Now $4.30 +23.76% ▲ +1.95% +2.88% vs SPY
- Jun 24, 202620w ago 8-K Neutral 3/10 Entry $5.52 to $5.25 Now $4.30 −22.10% ▼ −4.89% −6.45% vs SPY
- Jun 1, 202624w ago Insider Cluster Neutral 3/10 Entry $3.86 to $3.71 Now $4.30 +11.40% ▼ −3.89% −0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers